Neoadjuvant, Adjuvant, or Both? Optimizing Perioperative Systemic Therapy in Lung Cancer
Emily P Rabinovich1, Linda W Martin2
1Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA. Electronic address: https://twitter.com/EmilyRabinovich.
Abstract:
The evolving landscape of perioperative systemic therapy is transforming the management of resectable non-small cell lung cancer, addressing the limitations of adjuvant chemotherapy alone, the integration of novel therapies in the adjuvant and neoadjuvant settings, and biomarker-guided approaches. It discusses survival benefits associated with targeted therapies and immune checkpoint inhibitors, emphasizing the need for individualized and multidisciplinary strategies, as well as the optimal sequencing of these perioperative regimens.
More Related Videos
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
